-+ 0.00%
-+ 0.00%
-+ 0.00%
Meiji Seika Pharma to Invest in Arcturus Therapeutics
Share
Listen to the news
Meiji Seika Pharma to Invest in Arcturus Therapeutics
  • Meiji Seika Pharma announced November 17, 2026, an agreement to make a strategic investment in Arcturus Therapeutics, expanding their mRNA collaboration.
  • The companies signed a collaboration and exclusive license agreement covering ARCT-154 technology for an undisclosed therapeutic area.
  • A memorandum of understanding covers potential pandemic-response collaboration in Japan, including vaccine development using existing domestic COVID-19 vaccine manufacturing infrastructure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Meiji Holdings Co. Ltd. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending